Diabetes Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Diabetes Drugs Market
The diabetes drugs market size was valued at USD 79.25 billion in 2023, and the market is now projected to grow from USD 89.39 billion in 2024 to USD 153.98 billion by 2032, exhibiting a CAGR of 7.0% during the forecast period of 2024-2032.
The sales revenue declined due to limited patient access at healthcare facilities due to COVID-19. The pandemic however took a u-turn in 2021 as the soak in hospitalizations and diabetes detections escalated demand the diabetes drugs market growth in a bid to facilitate the proliferation of medications meant for diabetes treatment. Resultantly, the increase in the post-pandemic levels of hospital admissions and the launch of new diabetes remedies brought forth by active participants enabled the expansion of the market in 2021.
The rise in research and development investments and availability of low-priced insulin will enhance diabetes drugs market share at the same time high expenses related to standard therapies serve as market demand for new unbranded drugs like insulin. Also, there is an increase in demand for innovative blood sugar-regulating medications which increases diabetes drugs market share. Consequently, these elements will propel the market uphill during the stated period.”
Furthermore, rising awareness of diabetes and its complications is driving the high adoption of diabetes drugs globally. With high disease prevalence, industry players and governments are promoting increased drug adoption among diabetic patients. Various campaigns and funding initiatives are being launched to support these efforts, propelling market growth.
Comprehensive Analysis of Diabetes Drugs Market
The diabetes drugs market and healthcare industry are rapidly expanding due to detailed market segmentation. This growth is driven by the key supply and demand dynamics affecting the pharmacy industry. The market is divided by drug class, diabetes type, route of administration, and distribution channel. The drug class includes Insulin, GLP-1 Receptor Agonists, DPP-4 Inhibitors, SGLT2 Inhibitors, and Others. The diabetes type includes Type 1, and Type 2. The route of administration includes Oral, Subcutaneous and Intravenous. In the end distribution channel includes Online pharmacies, Hospital Pharmacies, and Retail Pharmacies.
North America is expected to lead the market on account of the increased budgets for research and development and growing instances of diabetes through 2023. This will push the region into market increases because of multiplied public recognition, new anti-diabetics as well as reimbursement guidelines.
Key industry players are essential in driving growth and establishing market standards within the healthcare industry, ensuring a positive outlook for the sector. These players include, Novo Nordisk A/S (Denmark), Sanofi (France), Merck & Co., Inc. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca (U.K.), Takeda Pharmaceutical Company Limited (Japan), Boehringer Ingelheim International GmbH (Germany), Novartis AG (Switzerland), Johnson & Johnson Services, Inc. (U.S.) and Bayer AG (Germany)
In January 2024, Glenmark Pharmaceuticals Ltd has just introduced a new diabetes product called Lirafit that goes for only 1.21 USD every day to get a 1.2 mg dosage of it.
Segmentation Table
GlobalDiabetes Drugs Market Scope
Study Period 2019-2032
Base Year 2023
Forecast Period 2024-2032
Growth Rate CAGR of 7.0% from 2024-2032
Historical Period 2019-2022
Unit Value (USD Billion)
Segmentation By Drug Class, Diabetes Type, Route of Administration, Distribution Channel, and Region
By Drug Class Insulin
DPP-4 Inhibitors
GLP-1 Receptor Agonists
SGLT2 Inhibitors
Others
By Diabetes Type Type 1
Type 2
By Route of Administration Oral
Subcutaneous
Intravenous
By Distribution Channel Online pharmacies
Hospital Pharmacies
Retail Pharmacies
By Region North America (By Drug Class, Diabetes Type, Route of Administration, Distribution Channel, and Country)
- U.S.
- Canada
Europe (By Drug Class, Diabetes Type, Route of Administration, Distribution Channel, and Country)
- Germany
- France
- U.K.
- Spain
- Italy
- Rest of Europe
Asia Pacific (By Drug Class, Diabetes Type, Route of Administration, Distribution Channel, and Country)
- China
- India
- Southeast Asia
- Japan
- Australia
- Rest of Asia Pacific
Latin America (By Drug Class, Diabetes Type, Route of Administration, Distribution Channel, and Country)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (By Drug Class, Diabetes Type, Route of Administration, Distribution Channel, and Country)
- GCC
- South Africa
- Rest of the Middle East & Africa
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Prevalence of Diabetes, by Type, for Key Countries / Region, 2023
- 4.2. Cost Burden, Diabetes, Key Countries, 2023
- 4.3. Pipeline Analysis, by Key Players
- 4.4. New Product Launches, by Key Players
- 4.5. Key Industry Developments Such as Mergers, Acquisitions, and Collaborations
- 4.6. Impact of COVID-19 on Global Diabetes Drug Market
- 5. Global Diabetes Drugs Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast – By Drug Class
- 5.1.1. Insulin
- 5.1.2. DPP-4 Inhibitors
- 5.1.3. GLP-1 Receptor Agonists
- 5.1.4. SGLT2 Inhibitors
- 5.1.5. Others
- 5.2. Market Analysis, Insights and Forecast – By Diabetes Type
- 5.2.1. Type-1
- 5.2.2. Type-2
- 5.3. Market Analysis, Insights and Forecast – By Route of Administration
- 5.3.1. Oral
- 5.3.2. Subcutaneous
- 5.3.3. Intravenous
- 5.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.4.1. Hospitals Pharmacies
- 5.4.2. Retail Pharmacies
- 5.4.3. Online Pharmacies
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
- 6. North America Diabetes Drugs Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast – By Drug Class
- 6.1.1. Insulin
- 6.1.2. DPP-4 Inhibitors
- 6.1.3. GLP-1 Receptor Agonists
- 6.1.4. SGLT2 Inhibitors
- 6.1.5. Others
- 6.2. Market Analysis, Insights and Forecast – By Diabetes Type
- 6.2.1. Type-1
- 6.2.2. Type-2
- 6.3. Market Analysis, Insights and Forecast – By Route of Administration
- 6.3.1. Oral
- 6.3.2. Subcutaneous
- 6.3.3. Intravenous
- 6.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 6.4.1. Hospitals Pharmacies
- 6.4.2. Retail Pharmacies
- 6.4.3. Online Pharmacies
- 6.5. Market Analysis, Insights and Forecast – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
- 7. Europe Diabetes Drugs Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast – By Drug Class
- 7.1.1. Insulin
- 7.1.2. DPP-4 Inhibitors
- 7.1.3. GLP-1 Receptor Agonists
- 7.1.4. SGLT2 Inhibitors
- 7.1.5. Others
- 7.2. Market Analysis, Insights and Forecast – By Diabetes Type
- 7.2.1. Type-1
- 7.2.2. Type-2
- 7.3. Market Analysis, Insights and Forecast – By Route of Administration
- 7.3.1. Oral
- 7.3.2. Subcutaneous
- 7.3.3. Intravenous
- 7.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 7.4.1. Hospitals Pharmacies
- 7.4.2. Retail Pharmacies
- 7.4.3. Online Pharmacies
- 7.5. Market Analysis, Insights and Forecast – By Country/Sub-region
- 7.5.1. U.K.
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Spain
- 7.5.5. Italy
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
- 8. Asia Pacific Diabetes Drugs Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast – By Drug Class
- 8.1.1. Insulin
- 8.1.2. DPP-4 Inhibitors
- 8.1.3. GLP-1 Receptor Agonists
- 8.1.4. SGLT2 Inhibitors
- 8.1.5. Others
- 8.2. Market Analysis, Insights and Forecast – By Diabetes Type
- 8.2.1. Type-1
- 8.2.2. Type-2
- 8.3. Market Analysis, Insights and Forecast – By Route of Administration
- 8.3.1. Oral
- 8.3.2. Subcutaneous
- 8.3.3. Intravenous
- 8.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 8.4.1. Hospitals Pharmacies
- 8.4.2. Retail Pharmacies
- 8.4.3. Online Pharmacies
- 8.5. Market Analysis, Insights and Forecast – By Country/Sub-region
- 8.5.1. Japan
- 8.5.2. China
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
- 9. Latin America Diabetes Drugs Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast – By Drug Class
- 9.1.1. Insulin
- 9.1.2. DPP-4 Inhibitors
- 9.1.3. GLP-1 Receptor Agonists
- 9.1.4. SGLT2 Inhibitors
- 9.1.5. Others
- 9.2. Market Analysis, Insights and Forecast – By Diabetes Type
- 9.2.1. Type-1
- 9.2.2. Type-2
- 9.3. Market Analysis, Insights and Forecast – By Route of Administration
- 9.3.1. Oral
- 9.3.2. Subcutaneous
- 9.3.3. Intravenous
- 9.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 9.4.1. Hospitals Pharmacies
- 9.4.2. Retail Pharmacies
- 9.4.3. Online Pharmacies
- 9.5. Market Analysis, Insights and Forecast – By Country/Sub-region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
- 10. Middle East & Africa Diabetes Drugs Market Analysis, Insights and Forecast, 2019-2032
- 10.1. Market Analysis, Insights and Forecast – By Drug Class
- 10.1.1. Insulin
- 10.1.2. DPP-4 Inhibitors
- 10.1.3. GLP-1 Receptor Agonists
- 10.1.4. SGLT2 Inhibitors
- 10.1.5. Others
- 10.2. Market Analysis, Insights and Forecast – By Diabetes Type
- 10.2.1. Type-1
- 10.2.2. Type-2
- 10.3. Market Analysis, Insights and Forecast – By Route of Administration
- 10.3.1. Oral
- 10.3.2. Subcutaneous
- 10.3.3. Intravenous
- 10.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 10.4.1. Hospitals Pharmacies
- 10.4.2. Retail Pharmacies
- 10.4.3. Online Pharmacies
- 10.5. Market Analysis, Insights and Forecast – By Country/Sub-region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis (2023)
- 11.2. Company Profiles
- 11.2.1. Sanofi
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT analysis
- 11.2.1.4. Recent developments
- 11.2.1.5. strategies
- 11.2.1.6. financials (based on availability)
- 11.2.2. Novo Nordisk A/S
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT analysis
- 11.2.2.4. Recent developments
- 11.2.2.5. strategies
- 11.2.2.6. financials (based on availability)
- 11.2.3. Eli Lily & Company
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT analysis
- 11.2.3.4. Recent developments
- 11.2.3.5. strategies
- 11.2.3.6. financials (based on availability)
- 11.2.4. AstraZeneca
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT analysis
- 11.2.4.4. Recent developments
- 11.2.4.5. strategies
- 11.2.4.6. financials (based on availability)
- 11.2.5. Takeda Pharmaceutical Company Limited
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT analysis
- 11.2.5.4. Recent developments
- 11.2.5.5. strategies
- 11.2.5.6. financials (based on availability)
- 11.2.6. Novartis AG
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT analysis
- 11.2.6.4. Recent developments
- 11.2.6.5. strategies
- 11.2.6.6. financials (based on availability)
- 11.2.7. Janssen Pharmaceuticals, Inc. (Johnson & Johnson Services Inc.)
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT analysis
- 11.2.7.4. Recent developments
- 11.2.7.5. strategies
- 11.2.7.6. financials (based on availability)
- 11.2.8. Bayer AG
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT analysis
- 11.2.8.4. Recent developments
- 11.2.8.5. strategies
- 11.2.8.6. financials (based on availability)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook